FDA to pull common but ineffective cold medicine from market
The FDA says oral phenylephrine, used in many over-the-counter cough and cold medicines, "is not effective as a nasal decongestant."
What is oral phynylephrine and why does the FDA want to remove it from cold medicine?
The U.S. Food and Drug Administration (FDA) is proposing to remove a common ingredient in nasal decongestants used by millions of Americans, citing data that shows it’s not effective. Oral phenylephrine is used in over-the-counter products like Sudafed and Dayquil to help temporarily relieve the common symptom of colds and allergies.
FDA wants to ban decongestant found in cold, allergy medicine
Dodgers' Shohei Ohtani Bid Pays Off: 2x MVP Rumored to Have Generated a Humongous 100M+ Revenue In His Debut Year Meet Ameca, the world's 'most advanced' humanoid robot What 50 legendary musicians looked like at the start of their careers 15 Foods That Barbara Bush Loved Stocks soared on news of Trump's election.
The FDA Is Finally Pulling a Useless Cold Medicine From the Market
Phenylephrine is both the most common decongestant on pharmacy shelves, and arguably the worst at its job. Last year, the FDA's advisory panel ruled it should no longer be considered an effective drug.
FDA proposes pulling ineffective cold medicine from shelves
When you’re feeling under the weather, you likely grab your go-to cough and cold medicine. But are all the ingredients helping you fight off that cold?
FDA Plans to Ban Ineffective Cold Medicine Ingredient—How It Will Affect You
The FDA had proposed removing phenylephrine, a widely used ingredient to treat nasal congestion, from over-the-counter cold medications. Here's what you need to know.
FDA Reviews Efficacy of Common Cold Medicines
The U.S. Food and Drug Administration (FDA) is currently evaluating the effectiveness of widely-used decongestants found in popular over-the-counter cold remedies such as Sudafed, Dayquil, and Mucinex.
FDA moves to pull popular cold and flu medicines from shelves
The FDA is proposing many popular over-the-counter cold and allergy medications be removed from store shelves. The agency says a common ingredient they share, phenylephrine, doesn’t actually relieve nasal congestion.
FDA considers pulling some cold medicine
FDA considers pulling some cold medicine
Yahoo Finance13d
Powerhouse Pilates in Common Brings Community-Focused Reformer Pilates Studio to Myrtle Beach's The Market Common
MYRTLE BEACH, S.C., Oct. 31, 2024 /PRNewswire/ -- Powerhouse Pilates in Common, a new boutique Pilates studio, will officially open their doors on January 1, 2025, at The Market Common ...
Morningstar2d
Is the Stock Market Open Today?
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Luxury Estate Built on Site of Infamous 'Mansion Murders' Property Hits the Market for $8.5 Million—9 Years After Horrifying Killings
An incredibly modern mansion that was built on the site of the infamous "Mansion Murders" home has hit the market for $8.5 ...
Daily Voice Calvert County MD on MSN4d
These Over-The-Counter Decongestants Don't Work, FDA Says
A common ingredient found in most oral over-the-counter cold medicines should be removed from the market because it doesn’t ...
Mises Institute5d
The Limits to Public Opinion and the Failure of Democracy
The question of restricting democracy came up because people tend to vote in ways that are contrary to their own interests in ...
Sonnet BioTherapeutics Announces Pricing of $5.0 Million Underwritten Public Offering Priced At-The-Market Under Nasdaq Rules
Sonnet BioTherapeutics Holdings, Inc. (the "Company" or "Sonnet”) (NASDAQ: SONN), a clinical-stage company developing ...
coloradopolitics1dOpinion
Common-sense Coloradans voted to not create ag, wildlife conundrums | GABEL
Voters didn’t place a higher value on the perceived happiness of sheep than on the very real ability of people to earn a ...
Modern Healthcare12d
FTC drills down on cross-market hospital mergers
Regulators are asking for more information on cross-market hospital merger proposals amid growing evidence of their potential ...